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COMMUNICATION  FROM  THE  COMMISSION 
TO  THE  COUNCIL.  THE  EUROPEAN  PARLIAMENT  ANQ  THE  ECONOMIC  ANQ  SOCIAL  COMMITTEE 
on 
BLOOD SELF-SUFFICIENCY 
IN THB EUROPEAN COMMUNITY I.  INTRODUCTION 
Increasing  concern  about  the  quality,  safety  and  supply  of human  blood  and  plasma 
products, particularly as a consequence of the AIDS  epidemic, served as background to an 
exchange of views  on  the  free  movement of blood  products  by  the  Ministers of Health 
meeting within the Council in November 1989. 
In 1  une  1989, in the framework of the development of the single mcu:.lret, the Council of the 
European Communities unanimously adopted Directive 89/381/EEC(l) extending the scope 
of existing  pharmaceutical  legislation  to  include  medicinal  products  derived from  human 
blood  or plasma  and  prepared  by  industrial  procedures.  The  Directive,  which  does  not 
apply to whole blood, plasma or blood celJs of human origin, has two main aims: 
introduction of stringent quality  and  safety  criteria for  medicinal  products 
derived from human blood and plasma, particularly in relation to preventing 
the transmission of viral diseases; 
promotion of self-sufficiency of the European Community in human blood 
or human plasma through voluntary and non-remunerated donations. 
With regard to self-sufficiency, the Directive provides that:  "Member States shall take the 
necessary  measures  to  promote  Community  self-sufficiency  in  human  blood  or  human 
plasma. For this purpose, they shall encourage the voluntary unpaid donation of blood and 
plasma and shall take the necessary measures to develop the production and use of products 
derived  from  human  blood  or human  plasma  coming  from  voluntary  unpaid  donations. 
They shall notify the Commission of such measures. " 
At  their meetings of 13  November  1989 and  11  November  1991,  the Council of Health 
Ministers addressed these issues further and requested the Commission to prepare a report 
on  the  subject of self-sufficiency  and  the  encouragement of voluntary  unpaid  donations 
within the Community. 
Given the previous work of the Council of Europe in this field,  and its continuing interest 
in this area,  it was  agreed that an enquiry into blood self-sufficiency should be conducted 
jointly. Ensuing difficulties in obtaining data from the Member States, however, resulted in 
delays in the preparation of the report. 
1.  Council  Directive of 14 June  1989 extending  the scope of Directives 65/65/EEC 
and 75/319/EEC on the approximation of provisions laid down by  law, regulation 
or administrative action relating to proprietary medicinal products and laying down 
special  provisions  for  medicinal  products  derived  from  human blood  or plasma. 
(0.1. L 181  of 28 June 1989, p.44-46). 2 
A Commission Staff Working Paper(2) presented to the  Health Council at its meeting of 15 
May  1992 mJtlined  the  major issues dealing with the  safety  21D1d  supply  of human blood  in 
the Community and afforded Council members the opportunity to reiterate the importance 
of  the  principles  outlined  in  the  Directive  and  their  keen  interest  in  receiving  the 
Cornmiss!on's Communication on the  su~ject of self-sufficiency.  Interest in  t..'lis  issue ·ili'a3 
again expressed at the Council's meeting of 13 November 1992. 
This Communication, prepared in response to the Council's request, is based on the results 
of the Joint enquiry conducted for the Commission and the Council of Europe by Professor 
Van  Aken  of the  Central  Laboratory of the  Netherlands  .Red  Cross  Blood  Transfusion 
Service, and takes into account the comments on his report(3) received from representatives 
of the Member States. 
2.  RATIONALE FOR SELF-SUFFICIENCY 
2. 1  Blood and its Derivatives 
The vital and indispensable nature of blood, which is comprised basicaUy of cells (red and 
white), platelets and plasma, and the fact that for therapeutic purposes humans are its only 
source at present, highlight the importance of ensuring its optimal use. This is achieved by 
separating it into  its  major constituents  and  whenever  appropriate using  these  instead  of 
whole blood  in  the  treatment of diseases  and injuries.  These constituents  can  be  divided 
into two main groups:  labile (or unstable), which have a sheRf life varying from a few days 
to one year dependling on the constituent itself as well  as the storage conditions; and stable 
medicinal products derived from blood or plasma, witDl a shelf life of several yem-s. 
Labile blood products include whole blood,  red blend cell concentrate,  white bUood cells, 
pDatelets,  Mdl  fresh  frozen  plasma.  Red  cell  replacement  is  the  fuermpy  of clhloice  when 
trmD.sfusnolllls  for  correcting  aurnaemia  are  required.  Red  ceil  coocelllltrates  aBoi11C,  or 
supplemelllted  witli  fresh  or frozen  plastru1  2llllldlor  serum  aDbtl!min,  are  effective  un  most 
patients for  untra-operative transfusiOIIllS.  Platenea:s are used for  priimll!'y  lliaelllOOSWis.  White 
bloOOI cells are used occasnooa.Dly for cases of severe septicemna. 
The  prirncipa~ stnble medncmml prorlucts derive(j)  from  bloOO  or plasmm mre:  aHbunmnlill,  wllticRl 
is  used  HJrimari.ly  for  resroriKng  or mmmtnnrung  bloorl  volume;  coag11llUatiollll  fmctors,  mclln  ms 
Fmctor  VKH,  req1llliroo  for  tremti!lllg  pmtients  wntln  llmemopllnmm;  nmmlllllOOgllobmHilillS  for 
preventing i111fectious ood munaoiil!llll!llliUBmle ruseares; Mitll othell" pllasl!l!llm proreilns. 
WllniDe  the  lmrgest  portion  of smbne  medkimll  pr~uncts derived  from  bU~  is  cul!'lrell1ltly 
extradoo  from  pRmsmm  collillJi.Jmg  from  whoRe  IMoOOI,  a  certmi!U  qjUOOaii\ty  CM  ~  oomim1erll  !by 
jplmsmapll!eresis - tfue  process illDvonvmg ilie removml of blcmll,  sepm:-maiiol!i  of tl1le  Moorll  cents 
by  Celllltrllfugation,  and!  remjectnoo  of the  pmc!Ied  ceUUs  s~ded  illl  m  runmbBe  Rlllliediumm.  In 
altlldiltion,  ilie  serum  pt>Irtlion  of p[acmtal  blood  ils  mlso  used  ms  sUurfung  Rlterimll  !for  abe 
preparation of aillbumi111  aundl  immwoogloftnnBms. 
2.  Towards  Increased  Cooperation  cmd  Coordination  in  the  lEu~  Commullllit:y  to 
Ensure  A<l!eq~~Jate  Blood  Availability.  (Commission  StaJff  Worl'ring  Pmper). 
SEC(92)360. 24 February 1992.  8p. 
3.  W.G. VanAken. The Collection and Use of Human Blood and!  PlC!ISma in Emope. 
Council of Europe.  1993. 31p. (ISBN 92-871-2240-7). 3 
In spite of the significant progress towards the synthesis of certain blood proteins and the 
existence of various substitutes, human blood is still irreplaceable. Therefore it is necessary 
to ensure: 
An  adequate supply of labile blood components which,  due to their limited 
shelf life, require expeditious use and frequent replacement; 
An adequate  supply  of blood or plasma as  source  material  for  use  in  the 
production of medicinal products. 
2.2  Self-sufficiency 
Availability of an ample supply of blood and appropriate blood products to an individual or 
group  of individuals  at the  time  of need  is  of the  utmost  importance.  To  ensure  this, 
reliance may be placed:  on  products derived solely from blood or plasma coming from a 
specific population of which the individual or group of individuals is a part;  on products 
coming from other populations; or on both. When reliance on products coming from other 
populations  has  been  eliminated  then  a  situation  of  self-sufficiency  for  the  specific 
population  in  question  is  considered  to  have  been  realized.  In  practise,  the  specific 
populations in question correspond to those of the various countries.  In order to minimize 
dependency  on  other  populations,  as  well  as  for  ethical  and  safety  reasons,  however, 
countries need to promote blood donations from  within their own populations and strive 
towards satisfying their clinical needs for blood and plasma from them. 
Ideally, the goal of self-sufficiency should be achieved through the promotion ·of voluntary 
and non-remunerated blood and plasma donations, in which the person gives blood, plasma 
or cellular components of his/her own free will without receiving payment, either in the 
form  of cash or in  kind  which  could be considered a  substitute  for  money.  This could 
include time off work other than that reasonably needed for the donation and travel. Small 
tokens,  refreshme~ts anqreimbursement of travel costs are compatible with voluntary, non-
remunerated donations. (4) 
2.3  PuabBic Health Aspects 
Because blood  is  vital to the life of numerous patients,  it is considered essential that its 
quality and safety be assured and that the health of the donors themselves is protected. 
Several viral, bacterial and parasitic diseases,  including AIDS,  hepatitis, and mataria, are 
transmissible  by  blood.  Some  are tested  for  specifically  and  some  are  not relevant for 
fractionated blood products. 
In  1987,  the  Council  took  the  view  that  the  European  Commmunity  pharmaceutical 
legislation should be extended to cover medicinal products derived from human blood and 
plasma.  In  1989,  the  Council  thus  adopted  Directive  89/381/EEC,  which covers  stable 
medicinal products derived from human blood or plasma.  Consequently, these products are 
now  subject  to  the  general  requirements  regarding  manufacturing  and  marketing 
authorization.  The,.. t?_I}.Rciples  of Good  Manufacturing Practice,  laid down  in Commission 
Directive 9113~/Ef.C\  5 J and detailed in a guide intended for manufacturers, as well as the 
4.  Definition  agreed  upon  by  the  Council  of  Europe  Blood  Transfusion  Expert 
Committee (SP-HM) and the League of Red Cross and Red Crescent Societies. 
5.  0.1. Nr L  193 of 17.7.91. 4 
testing  requirements  laid  down  in  Commission  Directive  911507/EEdEi),  have  become 
mandatory in order to demonstrate the quality, safety and efficacy of medicinal ·products ui 
view of their authorization.  In addition to these general requirements, which are applicab1e 
to  all  medicinal  products,  Directive  89/381/EEC  contains  certain  elements  whicl:!  are 
specific  for  blood  products,  such  as  the  implementation  by  manufacturers  of validated 
manufacturing  and  purification processes,  in  order to  ensure  as  far  as  possible  the  viral 
safety of these products.  To this  end,  the Committee for  Proprietary  Medicinal  Products 
(CPMP), in which the competent authorities of the Member States are represented, adopted 
two specific  notes  for  guidance  for  manufacturers  relating to  medicinal products derived 
from human blood or plasma and to validation of virus removal/inactivation procedures. 
The safety of labile blood components, including fresh plasma, is heavily dependent on the 
selection and testing of donors in order to prevent the transmission of disease.  ln spite of 
all the precautions, however, absolute safety cannot be guaranteed.  Risks can be minimised 
by  carrying  out  an  adequate  medical  consultation  in  combination  with  a  pertinent 
questionnaire, and conducting,  where necessary, an appropriate examination.  As a result, 
the donor can exclude himself/herself or be excluded from making a blood donation due to 
a specific pathology or a risk-factor identified during this process. If  necessary, the donated 
blood or certain components can be rejected as a result of abnormal laboratory screening 
results or because its exclusion has been requested. 
Care as  to  the  amount of blood provided by  donors,  as  well  as  by  those  who  undergo 
plasmapheresis,  must be exercised.  As  the capacity to replace proteins lost during blood 
donation is  not unlimited, excessive repetition particularly of plasmapheresis,  which is an 
industrial process carried out by both the non-profit and commercial sectors, can deprive a 
donor of his/her own plasmatic proteins and antibodies,  rendering him/her more sensitive 
to infection, and possibly susceptible to risks associated with malnutrition.  An equilibrium 
between quantity and frequency  is  needed since increasing either of these two parameters 
could  be detrimental  to  the  donor's  health;  maintaining  them  at relatively  lower  levels 
would  necessitate  an  increase  in  the  number  of donors  in  order  to  maintain  the  same 
volume of blood or plasma donated during a fixed period of time. 
Providing  material  benefits  to  blood  donors  in  the  form  of cash  or  in  kind,  or  other 
services,  is  contra-indicated:  for  clinical  reasons  - to  avoid  the  risk  of transmission  of 
infection to the recipient and to safeguard the health of the donor;  for social reasons - to 
ensure all  levels of society,  irrespective of economic status,  participate in donations;  and 
for  ethical reasons  - so as  not to exploit or deprive vulnerable population groups  either 
inside or outside the Community. 
It is desirable, therefore, that the fundamental principles of voluntary and unpaid donation 
of human blood, as accepted by the Council of Europe, the International Federation of Red 
Cross and Red Crescent Societies, and the International Society of Blood Transfusion, and 
recommended by the World Health Organization, are reaffinned. 
3.  THE STUDY ON SELF-SUFFICIENCY 
3 .1.  The Inquiry 
For more than 15  years, the Council of Europe has been a strong advocate of national self-
sufficiency  for  blood and  plasma products based  on voluntary  unpaid blood and plasma 
donations.  In  1988,  it conducted  an  enquiry on self-sufficiency based on voluntary non-
6.  O.J. Nr L 270 of 26.9.91. 5 
remunerated  donations  in  1986  that  resulted  in  the  publication  of a report(7)  ,  and  the 
adoption of "Recommendation R(90)9 of the Committee of Ministers to Member States on 
Plasma Products and European Self-sufficiency". 
Given the experience and continuing interest of the Council of Europe in this area, and the 
tact that its  efforts  to  promote  voluntary  unpaid blood and plasma donation,  as  stated  in 
Directive  89/381/EEC,  are  entirely  supported  by  the  Community,  it was  decided  that a 
joint Council of Europe/Commission enquiry should be conducted to ascertain the situation 
regarding self-sufficiency. 
In 1990, a questionnaire was distributed to the Heads of the Transfusion Services or to the 
responsible services of the Ministries of Health in Europe, including the  12 Member States 
of the  European Community,  to  elicit information about the  situation  as  it .  was  in  1989. 
Responses  were  submitted  to  Prof.  Van  Aken  who  analysed  the  results  and  prepared  a 
report. 
3.2  The Findings of the VanAken Report 
Despite  the  wealth  of data  provided  by  the  12  Member  States  in  responding  to  the 
questionnaire, Pt'esenting an accurate profile of the situation with regard to self-sufficiency 
in the Community in  1989 has proved difficult.  Some of the responses were not complete 
and data from one Member State to another were not always comparable.  Some data were 
not available,  some,  such  as  that from  non-public  sources,  were confidential,  and  some 
appeared to contradict those reported by  other sources.  Furthermore,  one  Member State 
provided data related to 1988 rather than to 1989. 
However,  based  on  the  results  of the  enquiry  and  information  obtained  through  direct 
contact with respondents Prof. VanAken reported, inter alia, that: 
3.2.1  The  unpaid  blood  donor  population  in  the  European  Community 
remained relatively stable from  1986 to 1989 at 8 to 9 million. 
3.2.2  The  number of whole  blood donations increased by about 5%  from 
14.7 million in 1986 to 15.4 million in 1989. 
3.2.3  In most Member States,  more than 75%  of whole blood collections 
were  separated  into  plasma  and  red  cell concentrates  before being 
transfused. Use of whole blood remained relatively high, however, in 
Portugal (30%), Greece (46%), and Italy (60%). Compared to  1986, 
the  relative  use  of both  red  blood  cell  and  platelet  concentrates 
increased in all countries. 
3.2.4  An  estimated  0.4  million  litres  of  plasma  could  be  saved  for 
fractionation if usage of whole blood was more closely monitored. 
3.  2.  5  There  was  a  marked  increase  ( +  151 %)  in  the  number  of unpaid 
donors  who  participated  in  plasmapheresis  rising  from  47,000  in 
1986 to at least 118,000 in 1989. 
3.  2.  6  More  than 3. 4  million  litres  of plasma  were  collected  in  1989  by 
means of whole blood donations and plasmapheresis. Of this amount, 
an estimated 0. 9 million litres were used directly for transfusions and 
--------------------
7.  ~?lasma Products and European Self-sufficiency: Collection, Preparation and Use. 
Council of Europe, 1992. 66p.  · 3.2.7 
3.2.8 
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an estimated 2.5 million litres were used for the production of plasma 
products.  The  exact  amount  of  plasma  collected  in  the  Federal 
Republic  of Germany,  however,  was  not  known  as  the  number of 
remunerated donations and the quantity of imported source  material 
was unknown. 
f mportations of plasma for  fractionation  from  outside  the European 
Community,  primarily  by the  Federal  Republic  of Germany,  Italy 
and Spain. were estimated at between 1.6 and 1.9 million litres. 
The two  plasma  products  that  play  a  dominant part in determining 
self-sufficiency  are  Factor  VIII  and  albumin.  For  Factor  VIII 
preparations,  total  consumption rose  from  500  million  International 
Units  (IU)  in  1986 to  614.9 million  IU  in  1989  - a  23%  increase. 
Consumption  in  Denmark,  France  and  Greece  appeared  to  have 
decreased. The mean usage per patient ranged from 0.4- 4.5 IU with 
variations  in  treatment  regimen  accounting  for  the  differences. 
Clinical use of Factor VIII showed a continuous increase since  1986 
largely because of its prophylactic administration to prevent bleeding 
episodes  and  chronic  joint  injury  in  persons  suffering  from 
haemophilia.  For albumin,  although  specific  questions regarding  its 
clinical  use  were  not  included  in  the  1989  enquiry,  estimated 
consumption varies between 200-500 kg per million in countries with 
fully-developed health care systems. 
From the responses, it was also determined that tor the year 1989 (1988 tor France): 
Belgium,  Greece,  France.  and  Luxembourg  reported  that  they  were  self-
sufficient  in  Factor  VIII  although  the  level  of use  varied  in  the  different 
countries.  Denmark,  Italy,  Netherlands,  and the  United  Kingdom expected 
to achieve it  between  1990 and 1994.  The situation in  the  Federal  Republic 
of Germany and Ireland was not clear. 
Denmark, the Federal Republic of Germany, France, Ireland, Luxembourg, 
and Netherlands reported self-sufficiency in albumin. Belgium, Italy, and the 
United Kingdom expected to reach it between 1990 and 1994.  The situation 
in Greece was unclear. 
Spain  and  Portugal  reported  that  they  were  not  self-sufficient  in  plasma 
products and gave no indication when they expected to be. 
Based  on  these  findings,  the  report  concluded  that  self-sufficiency  for  plasma  products 
derived from blood of unpaid donors is an attainable goal and several recommendations on 
how this could be achieved were presented. These were: 
Encouraging appropriate clinical  prescribing of medicinal  products derived 
from  human blood and plasma in  order to guarantee optimal use of plasma 
products. 
Increasing the  number of donors and/or donations  in  order to guarantee  a 
sufficient supply of plasma,  and  promoting plasmapheresis if this does not 
fully make up the shortage. 
Increasing the yield of fractionation procedures for Factor VIII. 
Promoting quality assurance of blood collection  in  all  Member States,  and 
identifYing the  origin (country  and type  of donation) of the  source  plasma 
when products are placed on the market in the Community. 7 
Ensuring  that . health  authorities  are  able  to  supply  data  regarding  the 
collection  and  use  of plasma products  so  as  to  facilitate  the  analysis  and 
monitoring  of developments  towards  self-sufficiency,  and  encouraging  the 
setting-up of a European data bank. 
4.  ISSUES RAISED BY MEMBER STATES 
To ensure that the report prepared by Professor VanAken accurately reflected the national 
situations in 1989,  consultations were held with scientific consultants and national experts 
from  the Member States and comments on both the factual and  su~jective or policy aspects 
·as well  as  the  recommendations,  were  elicited.  While  no  fundamental  objections  to  the 
overall  findings  nor to  the  general  thrust  of the  report were raised,  several  key  issues 
emerged relating to: 
- The principle of self-sufficiency. 
- The timeliness of the study. 
- The character of blood and plasma donations. 
- Blood Donors I Plasmapheresis. 
-Optimal Use_of Blood and Blood Derivatives. 
-Quality and Safety of Cellular Blood Products. 
- Information Exchange. 
4.1  The Principle of Self-sufficiency 
The principle of self-sufficiency, particularly in medicinal products derived from blood and 
blood  products,  is  viewed  as  a  goal  of  health  policy  and  continues  to  receive  the 
endorsement of the Member States. The degree to which this goal has been attained varies. 
Some  Member  States  already  have  reached  self-sufficiency  in  the  supply  of blood. and 
cellular constituents but still import plasma and plasma products, another has reached self-
sufficiency in whole blood for use in transfusions while pursuing a policy of seeking self-
sufficiency  in plasma-based products  sourced from  its  own volunteer donors,  and  others 
have not yet achieved self-sufficiency. 
While concensus on the principle of self-sufficiency exists,  there is  some ambiguity with 
regard to  j~ practical implementation.  The generally accepted definition, and that cited in 
the reportt  lS J,  links a population and its potential needs in blood and blood products to the 
same population  and the  satisfaction  of those  needs.  This  implies  that Community self-
sufficiency will  be achieved from within the Community itself.  Concern has been raised, 
8.  Self-sufficiency  - Provision  of human  blood  and  blood  products  from  within  a 
population to satisfY  the clinical needs of that population.  (CEC. 111/3602/90.  25 
January 1990.  Informal meeting of European experts on medicinal products derived 
from human blood or plasma. Brussels, 9-10 January 1990). however.  that  strict  adherence  to  this  definition  imposes  restrictions  on·  the 
importation/movement of  blood and blood products and hence impedes the clinical freedom 
of doctors to choose the most suitable product for individual patients, thus depriving .them 
of access  to  advances  in  blood  products,  many  of which  originate  in  commercial 
pharmaceutical  companies  outside  the  European  Community.  Whilst  rec:zing the 
legitimacy  of this  concern,  it was  noted  nevertheless  that  application  of  ·  practice 
contradicted the meaning of Community self-sufficiency and more accurately reflected the 
principle  of sufficiency  in  which  the  related key  factors  of need,  quality  and  safety, 
availability,  and  control  (Le assurance  with r~  to  quality,  safety  and  supply)  are 
assured and  tbr~  which the  clinical  needs  of patients,  and  concomitantly  the  clinical 
freedom of physiaans,  are taken into account.  It bas to be noted,  moreover,  that as  the 
provision refatfng to self-sufficiency in Directive 891381/EEC applies only to human blood 
or human plasma as  a starting material  for  the  manufacture of medicinal  products,  it is 
narrower in scope  than the  definition  presented above  and  that  cited  in  the  Van  Aleen 
report. 
The view tllat Community self-sufficiency should be brought about  throu~ national self-
sufficiency was also expressed by some Member States. How it will be achiev~ however. 
is up to 1he Member Stites  themselves.  Those  tbat have  achieved self-sufficiency could 
offer to or be called upon by the Member States that have not to make available surplus 
supplies  with preference  given  to products  comin~ from  voluntary  unpaid  donations. If 
supplies are not available ftom within the Community itself, however, then they will o.eed 
to be obtained from elsewhere. 
Conclusion 
The attainment of  self-sufficiency in blood and blood products at Community level 
through voluntary  non-remunerated donations  is the ultimate  goal  and  there  is  a 
clear obligation on Member States to promote this for medicinal products  derived 
from blood and plasma. 
4.2  Timeliness ofdle study 
A  ware of the fact that difficulties in obtaining the relevant data delayed the preparation of 
the report, Member  States nevertheless acknowledged that it addressed the situation with 
regard to self-sufficiency in the Community in 1989. Given that it  was based on data tbat is 
now more than dJree years old, however, it was deemed not to be a ~  foundation on 
which tD take decisions but could serve as a basis for further enminatlon of  the issue. 
In this regard, Member States agreed on the need to update the study on a regular basis in 
order that progress  within  the  Community  towards die  goal  of seff-sufficiency could  be 
measured and to supplement national data with data sought from industry. It was desinble 
that the  next U))date be  conducted  as  soon  as  possible and that the  compiled  data,  even 
though  incompfete,  accompanied  by brief explanations  be disseminated  quickly  with  the 
more extensive narrative to follow at a later date.  To facilitate this ~  particular!}' in 
the  compilation of the  data by the Member  States,  the  questionnaire  used  for  the  1989 
study, supplemented with questions of particular relevance to the phm:maceutical industry, 
was considered as the most appropriate way of obtaining the relevant data. 9 
COnclusion 
Recognizing the benefits that will accrue from  having  up-to-date information with 
regard  to  self-sufficiency  and  building  on  the  experiences  from  the  1989  study, 
mechanisms  should be put in place for  the  regular u~g  of the study  and  the 
timely dissemination of the results.  To facilitate this effort,  Member States should 
set up appropriate systems to improve their data collection. 
4.3  Cbaraetor of  Blood aacl Plasma Donations 
In keeping  with Directive  891381/EEC,  there  is  general  consensus  tbat blood donations 
should be neither induced nor rewarded either in kind or monetary terms.  This  tenet is 
adhered to strictly in some Member States but not in others. Although a significant amount 
of blood  and  plasma  is  donattxi  free-of-charge  and  material  benefits  in the  form  of 
pa~  in cash or in kind, or other services,  are not normally  provided nor are 1hey 
coDsidered desirable, incclltives to encourage blood and plasma donations do~- These 
incentives range  from the provision of small refreshments, ~  or little grailts,  to 
compensation for traDspol1ation costs, to days off  work for public service employees Jn one 
Member State and for all ~loyees  in another.  One Meniber State provides an  "expense 
allowance"  on a flat rate basis to compeusatc donors for loss of earnings due to time off 
worlt  to  give  blood,  costs  incm:red  in travelling  to  and  from  the  donor  centre,  and 
subsistence expenses,  although this "allowance" is not intended to be a fiDancia1 incentive 
to give blooci In another, a fee is paid to a donor organiz;.tion for blood donor recruitment 
publicey.  While  it is  acknowledged  that  some  gray  areas  exist in which  compensation 
would be deemed acceptable.  such as in the case of a donor with a rare blood type who 
must travel long distances to give the donation, this should be the exception rather-tb.an the 
ru1  .  - e. 
Although  the  pharmaceutical  industiy  currently  provides  compensation  for  blood  and 
plasma,  Directive  89/381/EEC  stipulates  that  it is  the  responsibility  of the  indMdual 
Member States to develop the production and use of products derived from hnmao blood or 
human plasma coming from voluntaiy unpaid donations. 
Conclusion 
The  principle of voluntary  aDd  tq»aid blood  donations  bas  been endorsed  and  is 
beiDg  suPPOrted by all Member States.  In practice,  however,  this ~leis  not 
strictly adhered to in an of them;  those which tolerate lax attitudes in this respect 
should  take  measures  necessary  to  eliminate  practices  which  UDdermine  tbis 
principle. 
4.4  Blood Dcmonl Plasmapheresis 
· An important factor in the effort to acbieve self-suffi.ciency.is the availability of sufficient 
resources.  How  best  to  ensure  this  is  still the  subject  of discussion.  Developing  and 
expanding plasmapheresis programmes,  which  is viewed by at lt"at one Member S1ate as 
the only way of achieving self-snfficiency,  bas been promoted in some countries to cover 
the need foi plasma ~- In some cases tbis is being done in cooperation with blood 
donor  services  and  the phannaceutical industiy.  The  idea that plasmapheresis  should  be 
stepped up only if supplies of whole blood donations are insufficient to meet requirelilents, 
however,  was  disputed on  the  grounds  that  plasma  from  plasmapheresis  is  superior  to 10 
plasma  from  whole-blood  donations  and  better  for  further  processing.  In  any  event,  the 
difference between the  recommended  limit on  the amount of plasma collected from  each 
donor per year,  as  cited in  the Van  Aken  report (15  litres)  and the  tigure quoted  in  the 
guidelines of the Medical Council of the Federal Republic of Gennany (25  litres) needs to 
be claritied. 
Efforts  are  underway  in  one  Member State to  increase  the  amount of plasma recovered 
from whole blood, which can be a cheaper method of obtaining material for fractionation. 
Nevertheless,  support was  given in the  Member States to continuing efforts in recruiting 
and  retaining  donors,  both  at regional  and  national  levels,  and  encouraging  cooperation 
between the bodies involved in recruiting donors  i.e. blood banks and the Red Cross. 
Conclusion 
Consideration should be given to developing, at an appropriate stage,  a basic set of 
principles at Community level to  be used in public awareness campaigns about the 
need  for  blood  donations  and  to  motivate  people  to  become  voluntary  unpaid 
donors, with the methodology to be the object of further deliberations. 
4.5  Optimal Use of Blood and Blood Derivatives 
In striving towards the goal of Community self-sufficiency, it is important to minimize the 
discrepancies  between  the  actual  needs  for  blood  and  blood  products  and  the  available 
resources.  Promoting the optimal use of blood and its derivatives is seen as an important 
way  of  achieving  this.  The  provision  of  information  to  hospitals  and  clinics,  the 
introduction of reporting procedures to record  the  use  of whole  blood  and plasma,  and 
inter-institutional  comparison  of the  medical  indications  on  whose  basis  given  blood 
products  are  administered,  were  suggested.  The  introduction  of  medical  audit  to  the 
National  Health  Service  in  the  United  Kingdom,  to  promote  the  optimal  use  of blood 
derivatives, and the establishment of a Blood Product Committee under the National Health 
Committee in  Denmark,  to  facilitate  discussions  between users and  producers as  well  as 
administrators  from  national  health  services  and  hospitals,  are  two  initiatives  already 
underway. 
In  addition,  the  importance  of infonning clinicians  about  the  optimal  use  of blood  and 
blood  products  and  the  role  of transfusion  physicians  in  this  regard  was  highlighted. 
Expanding  the  knowledge  of physicians  in  thts  area  through  the  development  of an 
appropriate training programme was sought by the Member States. 
Rationalization of treatment of patients within the European Community,  which will come 
about  as  a  result  of the  marketing  authorizations  for  medicinal  products  derived  from 
blood, will help to ensure the optimal use of blood and plasma. The adoption by the CPMP 
of harmonized  summaries  of  product  characteristics,  with  therapeutic  indications  and 
posologies,  for  the  20 main  plasma  derivatives,  is  also  a  valuable  contribution  towards 
optimal use. 
Conclusion 
To encourage the optimal use of blood and blood products throughout the Member 
States, mechanisms should be introduced to extend the knowledge of clinicians ar.d 
pertinent laboratory personnel related to transfusion medicine. 4.6  Quality and Safety of Blood-Products 
Ensuring the quality  and  safety  of blood and blood products  is  of major concern  to  the 
Member States.  With the  implementation of Directive  89/381/EEC,  however,  medicinal 
products derived from blood and plasma will be granted a marketing authorization only if 
their quality,  safety  and  efficacy  is  acceptable.  One  Member  State  emphasized  that  it 
considers blood as a medicinal product within the meaning of the law governing medicines, 
and therefore subject to statutory quality and safety requirements. 
Considering that the risks to  blood supplies  may  not be the same in all  countries,  some 
Member States considered that requirements for identical tests to be carried out throughout 
the  Community  were  not  appropriate.  While  certain  threats  are  common  to  all  blood 
supplies, such as HIV, others are not, and the view was expressed that flexibility should be 
maintained  in  keeping  with  Council  of  Europe  guidelines  which  allow  for  national 
variations in such matters as the tests to be applied to blood donations. 
To  ensure,  however,  that  differences  in  the  detailed · screening  tests  carried  out  in  the 
Member States did not become an obstacle to the free circulation of medicinal products, the 
CPMP adopted the note for guidance on Medicinal Products Derived from Human Blood or 
Plasma(9), which lays down harmonized tests on source material. Moreover, the European 
Pharmacopoeia  (Council  of Europe)  recently  adopted  a  monograph  which  lays  down 
screening
1
.tests  for  plasma  used  as  a  starting  material  for  the  manufacture  of blood 
products\ u). 
Regulations  governing  blood  donations,  which  provide  the  necessary  public  health 
safeguards  concerning  donors'  individual  health,  such  as  screening  to  detect  diseases 
transmissible by blood or plasma, such as hepatitis B, hepatitis C, and AIDS, have already 
entered into force in the Member States. 
Conclusion 
The  measures  that have  been implemented  within  the  Community  to  ensure  the 
quality, safety and efficacy of blood and plasma derivatives and the guidelines that 
have been developed by the Council of Europe for the screening of blood supplies 
should  help  to  reassure  patients  and  doctors  alike  with  regard  to  the  quality 
assurance of blood and blood products. 
4.  7  Information Exchange 
With the opening of the internal market, the sharing of experience and the regular exchange 
of information  is considered to  be an important and welcome process and of significant 
value  in  clarifying  misunderstandings,  in  finding  common  ground,  and  in  identifying 
differences.  A  European  data  bank  to  compile  this  information  could  facilitate  the 
monitoring of progress towards self-sufficiency and the changing policies and practices in 
the use of blood, blood components, and medicinal products. 
9. 
10. 
Rules Governing Medicinal  Products in the European Community.  Guidelines on 
the  Quality,  Safety  and  Efficacy  of Medicinal  Products for  Human  Use.  Volume 
III. Addendum 2. CEC. May 1992. p.lOl. 
Human Plasma for Fractionation. Council of Europe. 4p. 1993. Unpublished. 12 
Although  such a data bank would  i!~t solve the problem of European  self-sufficiency,  it 
would  facilitate  better analysis  and  monitoring of developments  towards  it.  Rather than 
cream a new central data bank,  how~ver, it wa.c;  thought to be more effective to utilize an 
already  existing  facili:t;y  and  to explore  ways  of expanding  its  role.  To  ensme  that the 
collection of  data did not create diffi.c!!lties and cause undue expense,  consideration should 
be given as to how best to ensure that only useful data woold be collected and to explore 
further what type of infonnation should be stored and updated in order to respond to the 
needs of the Member States. 
A  comparative  study  commissioned  by  Germany  on  procedures  in  Sweden,  ~ 
Netbc:rlands, tbe U  Dited Kingdom, and Germany could serve as a basis for identifying the 
type of information  to be collected  The results  of this study  will be available upon .  its 
completion in 1993. 
Conclusion 
Consideration  should  be  given  to  the  development  and  imp1ementation  of 
mcrlmrisms to faciJitate the sharing of experience aud the exchange of information 
to respond to the needs of  Member Snttes. 
S.  ACI'IONS FOR. CONSIDERATION 
In view of the continuing concern among the Member State$ about the quality, safety and 
supply of human blood and blood products, and taking into account the recommendations 
from  the VanAken report, the  comments from  the Member States,  and the conclusions 
reached  regarding  the  issues  raised,  the  Community  could  consider  undertaking  the 
following actious in its efforts to promote self-sufficiency in human blood or human plasma 
through volunt3Iy unpaid donations. 
Reinforcing the importance of  the goal of  self-sufficiency in  blood and blood 
tJI'Oducts at Co~  level while taking info account the progress achieved 
In the availability of  sUbstitnte medicinal products.  · 
Assessing the knowledge. attitudes and bebaviour of  the general public and 
~c  target  groups  in the  Member Sl~g  vo~  uilpaid 
blood dooatioos,  developing a basic set of  •  ·  at Community level to 
create public awareaess about the need for bloOd donations,  and fostt.ting 
programmes to motivate people to become donors. 
Gathering information on the various types of  remuneration 01" rewards liven 
to blood donors.  . 
Encouraging  the  optimal  use  of medicinal  products  derived  from  human 
blood and plasma and extending the knowledge of physicians involved  in 
transfusion medicine tbrougb the development of  information programmes. 
Promoting  qualit;y  assurance  of blood  collection  in  all  Member  States 
through adherence to the guidelines developed by the Council of  Europe~  · .  , 
. Updating the  report on self-sufficiency  in  the  Community,  using  a revised 
q·uestionnaire to include data from industry, and putting in pit>.ce  mechanisms 
for this to be done biannually. 
Facilitating. the exchange among the Member States of experiences acquired 
in  the·· Member  States  or  elsewhere  on  blood  donation  campaigns  and 
programmes and promoting discussions between the producers and the users 
of blood products. 
Assisting  Member States to  improve their data collection systems  so  as  to 
facilitate  the  analysis  and  monitoring  of  developments  towards  self-
sufficiency,  and  facilitating  the  sharing  of this  data  through  cooperative 
arrangements  . 
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